| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4600 | Sb1404 | PPARγ covalent ligand |
|
| DCC4601 | Sb1495 | Novel reversible covalent inhibitor of the cyclin-dependent kinase 5 (Cdk5)-mediated phosphorylation of PPARγ at Ser245, a key factor in the insulin-sensitizing effect of PPARγ-targeted drugs |
|
| DCC4602 | Sb1617 | Novel neuroprotective agent, suppressing abnormal tau protein aggregation |
|
| DCC4603 | Sb-203347 | Selective, active-site-directed 14 kDa PLA2 inhibitor, totally inhibiting LT and PAF formation, while prostanoid formation was not altered |
|
| DCC4604 | Sb-209670 | Dual ETA and ETB receptor antagonist |
|
| DCC4605 | Sb-220025 Trihydrochloride | Potent, specific inhibitor of human p38 mitogen-activated protein (MAP) kinase |
|
| DCC4606 | Sb-226552 | Potent and selective agonist for the human ß3-adrenoceptor |
|
| DCC4607 | Sb-239272 | Inhibitor of p38 MAPK |
|
| DCC4608 | Sb-243213 Dihydrochloride | Selective 5-HT2C_receptor>5-HT2C inverse agonist |
|
| DCC4609 | sb-258719 Hydrochloride | Selective 5-HT7 receptor antagonist |
|
| DCC4610 | Sb2602 | Novel selective mTOR inhibitor |
|
| DCC4611 | Sb-267268 | Nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reducing angiogenesis and VEGF expression |
|
| DCC4612 | Sb-277011a Dihydrochloride | Selective dopamine D3 receptor antagonist |
|
| DCC4613 | Sb-284851-bt | Selective p38a kinase inhibitor, inhibiting Brd4 |
|
| DCC4614 | Sb-354364 | AntiMycobacterium tuberculosis agent |
|
| DCC4615 | Sb-390570 | Novel TRPV4 blocker |
|
| DCC4616 | Sb-414796 | Potent and selective dopamine D3 receptor antagonist |
|
| DCC4617 | sb-649915 | Novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor |
|
| DCC4618 | Sb-656933 | Novel CXCR2 selective antagonist, inhibiting ex vivo neutrophil activation and ozone-induced airway inflammation in humans |
|
| DCC4619 | Sb-744941 | Novel inhibitor of mitogen and Stress-Activated Kinases 1 (MSK1) |
|
| DCC4620 | Sb-7720770 Dihydrochloride | Novel Rho kinase inhibitor |
|
| DCC4621 | Sb-790594-a | Potent non-cytotoxic inhinitor of Mycobacterium tuberculosis H37Rv |
|
| DCC4622 | Sbc040 | Novel cAMP-independent potentiator of CFTR, synergistically restoring CFTR function |
|
| DCC4623 | Sbc219 | Novel cAMP-independent potentiator of CFTR, synergistically restoring CFTR function |
|
| DCC4624 | Sbfi-am | Membrane-permeant, fluorescent, selective Na+ indicator dye |
|
| DCC4625 | Sbi-0061869 | Novel potentiator of metabotropic glutamate receptors for use against neurological and psychiatric disorders |
|
| DCC4626 | Sbi-0069332 | Novel potentiator of metabotropic glutamate receptors for use against neurological and psychiatric disorders |
|
| DCC4627 | Sbi-183 | Novel inhibitor of Quiescin Sulfhydryl Oxidase 1 (QSOX1), suppresses tumor cell growth in a Matrigel-based spheroid assay and inhibits invasion in a modified Boyden chamber, but does not affect viability of non-malignant cells |
|
| DCC4628 | Sbi4211 | Inhibitor of S100B which selectively kills melanoma; Amoebicidal diamidine |
|
| DCC4629 | Sbp-0636457 | Novel Smac mimetic, demonstrating potent cell-killing effects in several subtypes of breast, ovarian, and prostate cancer cell lines but only when the DR ligand TRAIL or another such apoptosis inducer is co-administered |
|
